secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001232524-23-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Q1 EPS $1.04, adj. $3.95; rev $893M (+10%); Xywav +49%, guidance affirmed
------------------------------------------------------------------------------

- GAAP net income $69.4M ($1.04 EPS) vs $1.6M ($0.03) in 1Q22; non-GAAP adj. net income $285.3M ($3.95 EPS) vs $261.9M ($3.73).
- Total revenue $892.8M (+10% YoY); neuroscience $654.0M (+7%), oncology $228.9M (+16%).
- Xywav net sales $277.8M (+49%), Epidiolex $188.9M (+20%), Rylaze $85.9M (+58%).
- FY 2023 guidance affirmed: rev $3.675-3.875B; GAAP EPS $5.90-$7.90; non-GAAP adj. EPS $16.90-$17.85.
- Pipeline: zanidatamab ASCO June 2, JZP150 PTSD Phase 2 top-line late 2023, suvecaltamide ET Phase 2b 1H24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252423000025/0001232524-23-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252423000025/jazz-20230510.htm
  HTML page:      https://secwatch.observer/filing/0001232524-23-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer